SGLT2 inhibitors
Longevity & Aging · covered by 12 outlets this week · tracked since 2026-10-27
Press: 8 specialist 11 independent outlet-days
Background
SGLT2 inhibitors (also called gliflozins or flozins) are a class of medications that inhibit sodium-glucose transport proteins in the nephron (the functional units of the kidney), unlike SGLT1 inhibitors that perform a similar function in the intestinal mucosa. Wikipedia ↗
Written by the Alivewire editors from the coverage below, 19h ago. Not medical advice; how the ratings work.
Coverage
HELP: analyse blood report
Rapamycin News · 12h ago
explainer
What are your thoughts about the following pharmaceuticals? How do you think a person should develop their stack
Reddit r/Biohackers · 1d ago
Anyone have experience with Sglt2 meds combined with Tirzepatide?
Reddit r/Biohackers · 5d ago
peer-reviewed
SGLT2 Inhibitors and GLP-1 Drugs Show Greater Kidney Benefits in Diabetes Patients With Albuminuria: BMJ
Medical Dialogues · 5d ago
studyobservational
SGLT2 inhibitors linked to small, consistent increases in haemoglobin and haematocrit
The Medical Republic · 6d ago
study
In T2D inadequately controlled with metformin, orforglipron reduced HbA1c more than dapagliflozin at 40 wk
Annals of Internal Medicine · 8d ago
ASN: Elderly with chronic kidney disease benefit from SGLT2 inhibitors
Medical Xpress · 9d ago
Research roundup
AJP (Australian Journal of Pharmacy) · 9d ago
Strong Moves for Healthy Aging: Smarter Nutrition, Next-Gen Rehab, and Personalized Exercise
Longevity101 · 12d ago
Why Empagliflozin’s Cardiovascular Benefit May Start in Your White Blood Cells
Rapamycin News · 12d ago
study
Comparing SGLT2 Inhibitors on Incident Major Adverse Kidney Events in Type 2 Diabetes: A Target Trial Emulation
Mayo Clinic Proceedings · 15d ago
study
Implications of the 2026 Cardiovascular-Kidney-Metabolic Syndrome Guideline for GLP-1 Receptor Agonist and SGLT2 Inhibitor Eligibility Among US Adults
medRxiv - Cardiovascular Medicine · 17d ago